ATOS - Breast Cancer-Focused Atossa Therapeutics Can Possibly Change Treatment Paradigm: Analyst | Benzinga
Cantor Fitzgerald has initiated coverage of Atossa Therapeutics Inc (NASDAQ: ATOS) with an Overweight rating and a price target of $5.
Analysts Louise Chen, Carvey Leung, Wayne Wu, and Lucas Olson Duffy say that the peak sales potential of ATOS' pipeline is underappreciated.
Cantor notes that the company's lead program (Z)-endoxifen, is a promising new selective estrogen receptor modulator (SERM).
According to published studies, (Z)-endoxifen is a competitive inhibitor of ERα and represses ERα transcriptional activity.
ATOS' (Z)-endoxifen has been shown to be well ...